Showing 3701-3710 of 7027 results for "".
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- New Report Highlights Challenges in Evaluating Biosimilarshttps://practicaldermatology.com/news/new-report-highlights-challenges-in-evaluating-biosimilars/2461933/New research provides an overview of gaps and challenges in the value assessment of biosimilars and identifies potential approaches to address them. The report, “
- Regenerative Medicine in Action: Turn Bio's ERA Technology Reprograms Skin Cellshttps://practicaldermatology.com/news/regenerative-medicine-in-action-turn-bios-era-technology-reprograms-skin-cells/2461930/Reprogramming with Turn Bio's ERA technology can rejuvenate cells within the extracellular matrix (ECM), resulting in changes related to improved skin quality and structure, according to a presentation at the AAD 2023 Innovation Academy in Tampa, Fla. ERA reprogramming tec
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic
- Bristol Myers Squibb’s New Sotyktu Campaign Reveals the Plain Truth About Living With Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibbs-new-clear-understanding-campaign-reveals-the-plain-truth-about-living-with-moderate-to-severe-plaque-psoriasis/2461914/Bristol Myers Squibb is rolling
- Evolus Rolls Out New Branding for Jeuveauhttps://practicaldermatology.com/news/evolus-rolls-out-new-branding-for-jeuveau/2461913/Evolus, Inc. is unveiling its new branding for Jeuveau (prabotulinumtoxinA-xvfs). The new Jeuveau imagery reflects today’s consumers, many of whom are millennials and younger. The “Jeuveau, You See Me” marketing campaign uses inclusive messaging to encourage
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for
- NPF Welcomes Four New Board Membershttps://practicaldermatology.com/news/npf-welcomes-four-new-board-members/2461907/The National Psoriasis Foundation (NPF) is adding four new members to the NPF Board of Directors. Andrew Blauvelt, MD, MBA, Valerie Harrison, PhD, Brian Janssen, and Diana Sandler, MD. will serve two-year terms effective July 1, 2023. Dr. Blauvelt will also serve as the Chair
- Revealed: Why Tans Appear After Leaving the Beachhttps://practicaldermatology.com/news/revealed-why-tans-appear-after-leaving-the-beach/2461906/New research uncovers the science behind why the body's tanning process does not occur immediately after sun exposure, but only after a few hours or even days. The mechanism that repairs our DNA takes precedence over all other systems in the cell, temporarily inhibiting the pi